ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

amrubicin

Also written as “Amrubicin”, “Amrubicin Hydrochloride” and “Amrubicin (Japan only)”.

Its studies are mostly in Small Cell Lung Carcinoma · Lung Neoplasms · Breast Neoplasms, led by 3 companies.

Drug pageAmrubicin: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 18, 20079 company-led studies, 1 open or runningNext primary completion: Oct 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb60 open or runningphase 3since Oct 18, 2007Apr 27, 2006none ahead
Sumitomo Pharmaits history only20 open or runningphase 3since Feb 1, 2006Feb 1, 2006none ahead
Gilead Sciencesits history only11 open or runningphase 3since Jan 24, 2025Jan 24, 2025Oct 2029phase 3 · NCT06801834

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2006First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT00319969 · 76 enrolled · United States
  2. Sep 9, 20062 phase 2 studiesNCT00375193, NCT00380835
  3. Oct 13, 2006Phase 2 study in Small Cell Lung CarcinomaNCT00388960 · 99 enrolled · Belgium, Italy, Netherlands and more
  4. Oct 18, 2007Phase 3 study in Small Cell Lung CarcinomaNCT00547651 · 637 enrolled · United States, Australia, Austria and more
  5. Jun 4, 2009Phase 1 study in Advanced Solid TumorsNCT00915083 · 24 enrolled · United States

TargetBeta

TOP2A →read by rule
“DNA topoisomerase II alpha inhibitor; DNA topoisomerase II alpha inhibitor”ChEMBL 37, by rule

Other programs on TOP2A

ProgramCompanyFurthest phaseStudies
DoxorubicinruleHoffmann-La Rochephase 461
EtoposideruleHoffmann-La Rochephase 328
Daunorubicinrulekura-oncology-incphase 37

Studies

All 6 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00915083Advanced Solid Tumors · United States1CompletedMay 1, 201124
NCT00547651Small Cell Lung Carcinoma · United States, Australia, Austria and more3CompletedMay 1, 2011637
NCT00388960Small Cell Lung Carcinoma · Belgium, Italy, Netherlands and more2CompletedApr 1, 201099
NCT00380835Breast Neoplasms · United States2Withdrawn66
NCT00375193Small Cell Lung Carcinoma · United States, Netherlands, United Kingdom2CompletedMay 1, 200875
NCT00319969Small Cell Lung Carcinoma · United States2CompletedJul 200876

How it is read

Names in the registry

  • “Amrubicin”, 6 entries
  • “Amrubicin Hydrochloride”, 2 entries
  • “Amrubicin (Japan only)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.